MarketCapExport financials
BioDelivery Sciences International (BDSI)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
BioDelivery Sciences International Income Statement 2021-2008 | BDSI
Brief overview of profit and loss at BioDelivery Sciences International
The figures are compared over a five-year interval. Revenue at BioDelivery Sciences International moved from 3.9 million dollars in 2016 to 167 million dollars in 2021. The total change was +4140.7%, with a CAGR of approximately 111.6%. This pace points to rapid expansion of the business.
Gross profit changed from $1.6 million to $143 million (+8687.9%). The cost base moved more slowly than the top line, which supported margins. Gross profit as a share of revenue changed from 41.5% to 86%. The margin shift points to a more favorable sales-and-cost structure.
The five-year EBITDA result moved by +352.4%: from −$14.8 million to $37.3 million. EBITDA lagged revenue, showing weaker operating momentum. EBITDA margin moved from −375.6% to 22.4%. The increased EBITDA share is a positive sign.
Comparing the endpoints shows a move from −$15.9 million to $84.9 million. The company restored profitability by the end of the period.
Market value was 93.9 million dollars at the start and 308 million dollars at the end. Capitalization grew more slowly than the underlying results.
Conclusion
The indicators form a favorable picture of business development. The positive side is supported by a stronger gross margin, sales growth and net-income growth. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement BioDelivery Sciences International
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
308 M | 419 M | 526 M | 234 M | 163 M | 93.9 M | 251 M | 581 M | 223 M | 132 M | 22.8 M | - | - | - |
Shares |
99.3 M | 99.8 M | 83.2 M | 63.2 M | 55.4 M | 53.7 M | 52.4 M | 48.4 M | 37.9 M | 30.5 M | 28.3 M | 23.2 M | 20.2 M | - |
Historical Prices |
3.1 | 4.2 | 6.32 | 3.7 | 2.95 | 1.75 | 4.79 | 12 | 5.89 | 4.31 | 0.805 | - | - | - |
Net Income |
84.9 M | 25.7 M | -15.3 M | -33.9 M | 5.28 M | -15.9 M | 10.2 M | -17.6 M | -57.4 M | 1.65 M | -23.3 M | -13 M | 33 M | - |
Revenue |
167 M | 156 M | 111 M | 18 M | 12.5 M | 3.93 M | 32.2 M | 2.55 M | 11.4 M | 54.5 M | 3.26 M | 3.4 M | 62.8 M | - |
Cost of Revenue |
23.4 M | 24.7 M | 21.6 M | 15.8 M | 19.5 M | 11.3 M | 8.1 M | 4.94 M | 2.08 M | 1.91 M | 1.76 M | 839 K | 2.04 M | - |
Gross Profit |
- | 33.9 M | 24.4 M | 14 M | 7.28 M | 1.63 M | 29.6 M | -516 K | 3.6 M | 19.1 M | 1.51 M | - | - | - |
Operating Income |
37.1 M | 33 M | 3.74 M | -4.45 M | -14.3 M | -15.2 M | 11 M | -18.4 M | -56.4 M | 7.06 M | -27 M | -16.3 M | 40.1 M | - |
Interest Expense |
-6 K | -3 K | 19 M | 10.2 M | 8.58 M | 3.27 M | 2.52 M | 2.02 M | 903 K | 33 K | 10.7 K | 25.9 K | -15.1 K | - |
EBITDA |
37.3 M | 33.5 M | 5.58 M | -3.71 M | -13.6 M | -14.8 M | 11.3 M | -18.2 M | -56.2 M | 7.53 M | -26.5 M | -15.9 M | 40.3 M | - |
Operating Expenses |
106 M | 98.8 M | 86.1 M | 63.5 M | 71.9 M | 68.2 M | 75.3 M | 72.7 M | 65.7 M | 45.6 M | 28.5 M | 18.9 M | 20.6 M | - |
General and Administrative Expenses |
106 M | 98.8 M | 86.1 M | 58.6 M | 58.9 M | 49.3 M | 54.7 M | 38.5 M | 12.3 M | 10.1 M | 7.61 M | 7.91 M | 8.4 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement BioDelivery Sciences International
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | - | - | - | 98.9 M | 98.7 M | 98.8 M | 101 M | 101 M | 101 M | 100 M | 97.1 M | 96.2 M | 89.6 M | 83.8 M | 71.3 M | 70.8 M | 64.9 M | 59.4 M | 58.1 M | 55.9 M | 55.6 M | 55.4 M | 54.5 M | 54.1 M | 53.8 M | 53.6 M | 52.2 M | 52.7 M | 52.5 M | 52.4 M | 51.9 M | 51.6 M | 49.6 M | 48.5 M | 44 M | 38.2 M | 38.1 M | 38 M | 37.5 M | 37.5 M | 30.1 M | 29.7 M | 29.6 M | 29.6 M | 29.6 M | 29.6 M | 25.1 M |
Net Income |
- | - | - | - | - | 6.67 M | 9.06 M | 5.24 M | 10.2 M | 9.38 M | 1.16 M | 4.97 M | -696 K | 354 K | -11.1 M | -3.83 M | -7.01 M | -6.38 M | -9.77 M | -10.7 M | -16.2 M | -12 M | -14.9 M | 48.3 M | -15.9 M | -16 M | -16.5 M | -18.7 M | 10.2 M | -20.4 M | -19.2 M | -8.19 M | -17.6 M | -36.6 M | -11.3 M | -4.64 M | -12.8 M | -18.5 M | -13.4 M | -12.7 M | 8.6 M | -17.5 M | 3.78 M | 6.75 M | - | -5.12 M | -5.1 M | -9.02 M |
Revenue |
- | - | - | - | - | 41.1 M | 41.4 M | 41 M | 42.2 M | 39.4 M | 36.6 M | 38.3 M | 31.6 M | 30.3 M | 29.7 M | 19.8 M | 18 M | 14.2 M | 12.2 M | 11.3 M | 12.5 M | 11.3 M | 8.74 M | 29.5 M | 3.93 M | 3.57 M | 5 M | 3.04 M | 32.2 M | 1.24 M | 1.73 M | 13.1 M | 2.55 M | 1.82 M | 13.9 M | 20.7 M | 3.97 M | 3 M | 2.76 M | 1.62 M | 19.9 M | 1.88 M | 16.3 M | 16.5 M | - | 2.66 M | 38.4 K | 229 K |
Cost of Revenue |
- | - | - | - | - | 6.36 M | 4.28 M | 5.82 M | - | 5.38 M | 5.44 M | 5.56 M | - | 5.35 M | 4.92 M | 4.05 M | - | 3.78 M | 4.57 M | 3.42 M | - | 4.44 M | 4.17 M | 5.64 M | - | 2.31 M | 4.09 M | 2.55 M | - | 1.7 M | 2.62 M | 1.12 M | - | 463 K | 687 K | 726 K | - | 643 K | 690 K | 375 K | - | 375 K | 375 K | 375 K | - | 1.51 M | -426 K | 297 K |
Gross Profit |
- | - | - | - | - | - | - | - | 33.9 M | 34.1 M | 31.1 M | 32.7 M | 24.4 M | 25 M | 24.8 M | 15.7 M | 14 M | 10.4 M | 7.61 M | 7.87 M | 7.28 M | 6.81 M | 4.57 M | 23.8 M | 1.63 M | 1.26 M | 910 K | 490 K | 29.6 M | -464 K | -888 K | 11.9 M | -516 K | 1.36 M | 13.2 M | 20 M | 3.6 M | 2.35 M | 2.07 M | 1.25 M | 19.1 M | 1.5 M | 15.9 M | 16.1 M | - | - | - | - |
Operating Income |
- | - | - | - | - | 9.26 M | 11.4 M | 7.44 M | 12.5 M | 11.6 M | 2.94 M | 5.98 M | 613 K | 1.6 M | 2.8 M | -1.27 M | -4.45 M | -3.81 M | -7.27 M | -8.12 M | -14.3 M | -10 M | -13 M | 7.9 M | -15.2 M | -15.2 M | -15.6 M | -17.9 M | 11 M | -19.7 M | -18.7 M | -7.8 M | -18.4 M | -19.1 M | -2.04 M | 713 K | -11.8 M | -17.1 M | -13.8 M | -13.7 M | 5.41 M | -14.1 M | 7.15 M | 8.56 M | - | -7.67 M | -6.21 M | -8.54 M |
Interest Expense |
- | - | - | - | - | 1.98 M | 2 M | 1.98 M | - | 2.01 M | 1.69 M | 1.29 M | - | 1.23 M | 13.9 M | 2.56 M | - | 2.57 M | 2.52 M | 2.5 M | - | 1.89 M | 1.88 M | 2.89 M | - | 786 K | 914 K | 778 K | - | 785 K | -3 K | 27 K | - | 2.13 K | 9.05 K | 23.3 K | - | -35.4 K | -95.5 K | -23.2 K | - | 16.4 K | 50.3 K | -3.46 K | - | 15.2 K | 11.9 K | -27.9 K |
EBITDA |
- | - | - | - | - | 9.36 M | 11.4 M | 7.46 M | 12.5 M | 12.1 M | 3.38 M | 6 M | 613 K | 1.85 M | 2.97 M | -1.19 M | -4.45 M | -3.61 M | -7.07 M | -7.89 M | -14.3 M | -9.84 M | -12.9 M | 8.01 M | -15.2 M | -15.1 M | -15.5 M | -17.9 M | 11 M | -19.6 M | -18.6 M | -7.72 M | -18.4 M | -18.3 M | -1.53 M | 1.04 M | -11.8 M | -16.1 M | -13.1 M | -13.3 M | 5.41 M | -12.9 M | 7.89 M | 8.94 M | - | -6.68 M | -5.55 M | -8.21 M |
Operating Expenses |
- | - | - | - | - | 25.5 M | 25.8 M | 27.8 M | - | 22.5 M | 28.2 M | 26.7 M | - | 23.4 M | 22 M | 17 M | - | 14.2 M | 14.9 M | 16 M | - | 16.9 M | 17.6 M | 15.9 M | - | 16.5 M | 16.5 M | 18.4 M | - | 19.2 M | 17.8 M | 19.7 M | - | 20.4 M | 15.2 M | 19.3 M | - | 19.4 M | 15.9 M | 15 M | - | 15.6 M | 8.78 M | 7.58 M | - | 8.83 M | 6.67 M | 8.47 M |
General and Administrative Expenses |
- | - | - | - | - | 25.5 M | 25.8 M | 27.8 M | - | 22.5 M | 28.2 M | 26.7 M | - | 23.4 M | 22 M | 17 M | - | 13.5 M | 14 M | 13.5 M | - | 14.9 M | 16 M | 13.3 M | - | 12.1 M | 12.5 M | 13.1 M | - | 14.7 M | 13.3 M | 13.2 M | - | 13.6 M | 7.25 M | 4.62 M | - | 3.04 M | 3.11 M | 2.91 M | - | 2.99 M | 2.21 M | 2.84 M | - | 2.59 M | 1.93 M | 1.76 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company BioDelivery Sciences International (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
France
Israel
Japan
Canada
Schweiz
China
Germany
Britain
